Please enable Javascript
Advanced Urothelial Carcinoma
Advertisement
ICI Use Points to Attrition of Novel Second-line Treatment for mUC
Emily Menendez
Advanced Urothelial Carcinoma
|
March 14, 2024
While ICIs have become a novel treatment option for mUC, attrition rates may affect their impact on long-term survival.
Read More
Dr. Guru Sonpavde on Nivolumab, Gem-Cis FDA Approval and Role in Treating Metastatic Bladder Cancer
Guru P. Sonpavde, MD
Advanced Urothelial Carcinoma
|
March 12, 2024
Dr. Sonpavde provides an overview of the potential of nivo/gem-cis for patients with mUC who are ineligible for EV/pembro.
View More
FDA Approves Nivolumab With Cisplatin-Gemcitabine for Unresectable or Metastatic UC
Zachary Bessette
Advanced Urothelial Carcinoma
|
March 7, 2024
Approval came as a result of the CheckMate 901 study, a randomized trial that enrolled 608 patients with metastatic UC.
Read More
EV Maintains HRQOL in Patients With Previously Treated Advanced UC
Emily Menendez
Advanced Urothelial Carcinoma
|
March 6, 2024
Patients who received EV over chemotherapy maintained their HRQOL levels and experienced delayed HRQOL deterioration.
Read More
Long-term Follow-up of TROPHY-U-01 Shows High ORR in Patients With UC
Emily Menendez
Advanced Urothelial Carcinoma
|
February 28, 2024
Patients with mutations in the UGT1A1 gene can experience adverse events when treated with irinotecan-based therapies.
Read More
Subgroup Analyses and Progression After EV-302
Thomas Powles, MBBS, MRCP, MD
Advanced Urothelial Carcinoma
|
March 7, 2024
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
View More
UNITE Study: Sequencing Erdafitinib and EV for Patients With FGFR2/3-Altered Disease
Vadim Koshkin, MD
Advanced Urothelial Carcinoma
|
February 12, 2024
The potential for sequencing erdafitinib and EV for patients with FGFR2/3-altered disease is considered.
View More
UNITE Study: Impact of Squamous, Other Histologies on Outcomes With EV
Vadim Koshkin, MD
Advanced Urothelial Carcinoma
|
February 12, 2024
The impact of squamous and other histologies on outcomes with EV are dissected.
View More
UNITE Study: Design, Patients Sampled, and Outcomes With EV After Switch Maintenance Avelumab
Vadim Koshkin, MD
Advanced Urothelial Carcinoma
|
February 12, 2024
The design of UNITE, patients sampled, and outcomes with EV after switch maintenance avelumab are explored.
View More
Sacituzumab Govitecan Offers Higher Response Rates Than Pembrolizumab in Patients With mUC
Emily Menendez
Advanced Urothelial Carcinoma
|
February 12, 2024
With a high response rate and manageable toxicity, further research into the use of SG in patients with mUC is warranted.
Read More
Avelumab Maintenance for Advanced UC: Updates From JAVELIN Bladder 100, US PATRIOT-II, and More
Petros Grivas, MD, PhD
ASCO GU Symposium 2024
|
February 5, 2024
Dr. Grivas describes the advancements in the discussion around avelumab maintenance at this year's meeting.
View More
AMBASSADOR and PemCab: Trials of Note for Advanced Bladder Cancer
Guru P. Sonpavde, MD
ASCO GU Symposium 2024
|
February 4, 2024
Dr. Sonpavde provides a detailed overview of 2 of the bladder cancer trials of note: AMBASSADOR and PemCab.
View More
AI Modeling, KEYNOTE-992, MAIN-CAV, and Platinum-Eligibility Criteria in Bladder Cancer
Shilpa Gupta, MD
ASCO GU Symposium 2024
|
January 27, 2024
Dr. Gupta details some of her latest research and describes the importance of multiple new initiatives in bladder cancer.
View More
Subgroup Analyses Offer New Understandings of EV, Pembrolizumab Benefit in la/mUC
Zachary Bessette
ASCO GU Symposium 2024
|
February 5, 2024
Improved outcomes in patients with previously untreated la/mUC after EV/pembro, even in poor prognosis patient subgroups.
Read More
AMBASSADOR: Adjuvant Pembrolizumab in Muscle-Invasive, Locally Advanced UC
Zachary Bessette
ASCO GU Symposium 2024
|
February 1, 2024
Adjuvant pembrolizumab demonstrates improvement in DFS for patients with high-risk MIUC after radical surgery.
Read More
JAVELIN Bladder 100: Long-term Patient-Reported Outcomes
Zachary Bessette
ASCO GU Symposium 2024
|
January 25, 2024
Prolonged avelumab first-line maintenance treatment is associated with stable PROs for those with aUC.
Read More
Erdafitinib, EV Combination Shows Antitumor Activity in mUC With FGFR2/3 Alterations
Zachary Bessette
ASCO GU Symposium 2024
|
February 1, 2024
An early-stage trial highlights the antitumor activity from erdafitinib plus EV for mUC with FGFR2/3 genetic alterations.
Read More
Cabozantinib Plus Pembrolizumab Shows Promise in Treating Advanced mUC
Katy Marshall
ASCO GU Symposium 2024
|
February 1, 2024
Patients received pembrolizumab 200 mg every 3 weeks and cabozantinib 40 mg daily.
Read More
FDA Approves Erdafitinib for FGFR3-Positive Metastatic Urothelial Carcinoma
Zachary Bessette
Advanced Urothelial Carcinoma
|
February 16, 2024
The FDA has approved erdafitinib for adult patients with mUC and susceptible FGFR3 genetic alterations.
Read More
A New Era in Bladder Cancer Research: Breakthroughs and Insights From 2023
David Ambinder, MD
Urothelial Carcinoma
|
January 16, 2024
Approximately 40 clinical trials related to bladder cancer were published at the end of 2022 and throughout 2023.
Read More
Load More
Advertisement
Advertisement
Advertisement